LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.7 4.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.58

Max

1.75

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+130.49% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	158M 652M
Eelmine avamishind	-2.59
Eelmine sulgemishind	1.7

Uudiste sentiment

By Acuity

46%

54%

147 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Diana Shipping Increases Offer to Acquire Genco -- Update

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6. märts 2026, 22:26 UTC

Uudisväärsed sündmused

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6. märts 2026, 22:07 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

6. märts 2026, 21:37 UTC

Tulu

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6. märts 2026, 21:25 UTC

Uudisväärsed sündmused

How The Iran War Impacts Ukraine. -- Barrons.com

6. märts 2026, 21:17 UTC

Tulu

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6. märts 2026, 20:50 UTC

Tulu

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6. märts 2026, 20:46 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6. märts 2026, 20:31 UTC

Uudisväärsed sündmused

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6. märts 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6. märts 2026, 20:12 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6. märts 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6. märts 2026, 18:44 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6. märts 2026, 18:08 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6. märts 2026, 17:46 UTC

Uudisväärsed sündmused

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6. märts 2026, 17:40 UTC

Market Talk

Tulu

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6. märts 2026, 17:40 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 17:32 UTC

Market Talk

Uudisväärsed sündmused

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6. märts 2026, 17:28 UTC

Market Talk

Uudisväärsed sündmused

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

6. märts 2026, 17:20 UTC

Omandamised, ülevõtmised, äriostud

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

130.49% tõus

12 kuu keskmine prognoos

Keskmine 3.78 USD 130.49%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

147 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.